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Summary In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we
prospectively followed 312 breast cancer (BC) patients, from October 1988 to March 1995, from the time of first relapse. CA 15-3 values were
assessed before treatment onset. Disease extent was defined as the percentage of liver or lung involvement and the number of bone
segments positive at scintigraphy. The covariates were primary tumour characteristics (T, N and hormone receptor status) and patient
characteristics at recurrence (menopause, performance status and age). Higher CA 15-3 serum levels were found in patients with visceral
metastases or with pleural effusion. A logistic regression model selected disease extent in liver, lung and bone as independent variables for
the determination of abnormal CA 15-3 values. Univariate survival analysis confirmed the positive prognostic influence of low CA 15-3 serum
levels, absence of visceral metastases and the presence of only one metastatic site. Multivariate Cox's survival analysis selected disease
extent in liver, lung, bone and soft tissue but not level of CA 15-3 as prognostic factors. In conclusion, CA 15-3 is not an independent variable
in determining survival, its prognostic role being linked to the disease extent. This association suggests that CA 15-3 may be useful in
assessing disease extent when this is not easily assessable.
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Metastatic breast cancer is a national health problem in Italy (La
Vecchia et al, 1990) and also in Western countries (Hayes et al,
1995). In fact, approximately 10% ofnewly diagnosed patients will
present with metastatic disease, and an additional 50-75% will
eventually relapse (Overmoyer, 1995). The treatment for metastatic
disease is palliative (Clavel and Catimel, 1993; Gregory et al, 1993;
Chlebowski and Lillington, 1994). For this reason, there has been
little interest in the search for prognostic parameters for metastatic
patients. Untilrecently,TNM stage,steroidhormone receptorstatus,
disease-free interval (DFI) and dominant site of metastasis have
been therecognized prognostic factors in advanced disease (Clark et
al, 1987; Henson et al, 1991; Koenders et al, 1992). However, most
of them refer to tumour characteristics at diagnosis that may not
always be available at recurrence. Additional prognostic features at
relapse are needed. The presence of visceral metastases has been
related to poor prognosis (Clark et al, 1987; Koenders et al, 1992).
However,patients with visceral involvement exhibit a wide survival
range, mainly dependent on organ-tumour burden (Zinser et al,
1987). The assessment ofthe extent ofdisease is generally difficult
in practice and is usually restricted to the comparison of patients
with single vs multiple organ involvement (Clark et al, 1987).
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CA 15-3, the most widely used circulating tumour marker in
breast cancer patients, is useful in monitoring the response to treat-
ment and gives reliable information on the recurrence of disease
(Safi et al, 1989; Dogliotti et al, 1990; Soletormos et al, 1993;
Yadav et al, 1993; Gion et al, 1994). Colomer et al (1989) demon-
strated a significant relationship between serum CA 15-3 levels and
the overall tumour load in patients with advanced disease. We
recently showed (Berruti et al, 1994) that elevated serum CA 15-3
values and visceral metastases are independent variables in
predicting overall survival at thetime offirstrelapse ofdisease. The
aim of the present study was to evaluate the relationship between
serum CA 15-3 levels and the tumour load at firstrelapse ofdisease
in predicting survival ofmetastatic breast cancer patients.
MATERIALS AND METHODS
Patients
From October 1988 to March 1995, 312 patients with advanced
breast cancer entered the study, of whom 195 were treated and
followed at the Servizio di Oncologia Medica, Azienda
Ospedaliera San Luigi, Orbassano, Turin, Italy. The remaining 117
patients were recruited from four other institutions involved in a
multicentre randomized trial comparing the activity ofsingle-agent
epirubicin with epirubicin plus lonidamine (Dogliotti et al, 1996).
All patients were previously submitted to quadrantectomy plus
radiation therapy or modified mastectomy when indicated, both
associated to axillary node dissection. Adjuvant chemotherapy
with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) was
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administered in premenopausal patients with lymph node involve-
ment or steroid hormone-negative tumour and in post-menopausal
patients with oestrogen receptor (ER)-negative tumour and lymph
node invasion. Adjuvanttamoxifen was administered in node-posi-
tive post-menopausal patients with hormone-dependent tumours.
Limited locoregional recurrences were treated with radical surgery
followed by radiotherapy. Post-menopausal patients with either
bone or soft tissue metastases, the latter not suitable for radical
surgery, and steroid hormone receptor-positive primary tumours
received endocrine therapy (tamoxifen, aminoglutetimide, medro-
xyprogesterone acetate). Premenopausal patients with visceral
metastases or with progressive disease after first-line hormone
therapy for advanced disease received an anthracycline-based
chemotherapy (FEC: fluorouracil, epirubicin, cyclophosphamide;
epirubicin at 120 mg m-2± lonidamine). Clinical information was
obtained by chart or CRF reviews and included T, N, hormone
receptor status and DFI. Time of first relapse, age, menopausal
status and performance status (ECOG scale) were also recorded.
Patients were categorized as premenopausal if menses had
occurred within 1 year before study entry and post-menopausal if
last menses occurred more than 1 year before disease recurrence.
Inclusion criteria were: (1) patients with clinical and/or radio-
logical proof of relapse and (2) CA 15-3 evaluation within 1
month from diagnosis of metastatic disease and before any treat-
ment onset.
Exclusion criteria were renal (creatinine > 1.5 mg dl-' or urea
> 60 mg dl-') or liver (bilirubine > 2.0 mg dl-') impairment and
concurrent neoplastic diseases.
Assessment of the disease extent
Recurrences were classified as visceral (brain, liver, lung or other
sites), bone or soft tissue. Metastatic sites were documented by
physical examination, scintigraphy, radiography and/or computer-
ized tomography (CT) scan. Only the first site ofmetastasis, either
locoregional or distant, was recorded and evaluated. When more
than one organ was concomitantly involved, the hierarchy of
recurrences that progressively worsened the prognosis was
assumed to be soft tissue, bone and visceral.
The disease extent was defined in accordance with the method
proposed by Swenerton et al (1979) and modified by Colomer et al
(1989). In brief, the extent at each site was defined on a four-point
scale on which 0 was no disease; 2 minimal involvement; 5
moderate involvement; and 10 extensive involvement. The disease
extent was independently evaluated by three investigators who
remained blinded from the results of serum CA 15-3 assessment.
Final score was determined by the concordance of at least two
physicians or by the estimation of more extensive disease. Total
burden ofmetastatic disease was estimated adding the scores ofall
known disease sites.
Marker assay
CA 15-3 serum levels were evaluated by five different laboratories
using commercial two-step immunoradiometric assay (IRMA)
kits. Serum samples were immediately frozen at -200C after
collection and analysed within 15 days. The lowest detection level
was 5 U ml-'. Intra- and inter-assay variability was superimpos-
able for the five laboratories and was within 3.5-4% and 6-7%
respectively. Inter-laboratory discordance was never greater than
8%. The uppernormal concentration was assumed to be 30 U ml-'.
Table 1 Patients' characteristics
No. of patients
Median age (years)
Premenopausal
Menopausal
Men
Stage at diagnosis
IV
IVI
Unknown
Hormone receptor status
ER,
PgR+
Adjuvant therapy
Chemotherapy
Endocrine therapy
Disease-free interval
Median 28.4, range 0-339 months
<24 months
.24 months
Unknown
Performance status
0-1
2-3
Dominant metastatic site
Liver
Lung
Bone
Soft tissue
No. of recurrence sites
1
2
>2
Clinical course
Alive
Dead
Lost to follow-up
312
57 (30-82)
83 (27%)
225 (72%)
4 (1%)
23 (7%)
100 (32%)
22 (7%)
71 (23%)
96 (31%)
115/182 (63%)
93/182 (51%)
207 (66%)
43 (14%)
124 (40%)
152 (49%)
36 (11%)
270 (87%)
42 (13%)
77 (25%)
116 (37%)
87 (28%)
32 (10%)
203 (65%)
81 (26%)
28 (9%)
113 (36%)
187 (60%)
12 (4%)
Statistical analyses
Differences between proportions were evaluated by the Chi-square
test with Yates' correction, when necessary. Differences in serum
CA 15-3 concentrations were analysed using the Mann-Whitney
U-test for unpaired non-parametric variables and/or with
Kruskal-Wallis one-way analysis ofvariance (ANOVA). Multiple
regression was performed to eliminate confounding variables.
Overall survival was measured from the time of first recurrence
until death and represented with univariate analysis with the
Kaplan-Meier product limit method. Patients who were alive at
the time ofdata computation or lost to follow-up were censored at
the time ofthe last follow-up examination. Differences in survival
were validated using the log-rank test. Potential prognostic factors
were analysed in a multivariate analysis using Cox's proportional
hazards model. All these statistical computations were performed
using the SPSS software package (Nie et al, 1988).
RESULTS
Patient demography
As outlined in Table 1, at diagnosis most patients had early stages
of disease. Receptor status was recorded in 182 patients (58%).
T%wo hundred and fifty patients (80%) had received adjuvant
endocrine therapy or chemotherapy. One hundred and twenty-four
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Table 2 CA 15-3 and survival according to disease extent
Disease extent CA 15-3 Median survival
(score) Mediana Sensitivity (months)
< 5 29 45% (63/140) 30.5
6-10 87 70% (45/64) 25.3
11-15 122 74% (14/19) 19.2
> 15 159 89% (8/9) 10.7
P-value < 0.001b < 0.001C p < 0.006d
aDetermined only for the 195 patients followed by our institution.
Kruskal-Wallis ANOVA. cChi-square test. dLog-rank test.
Table 3 Univariate survival analyses
Variable Survival (months) P
Dominant metastatic site
Visceral 22.2
Not visceral 30.7 < 0.001
Liver 14.4
Lung 24.7
Bone 29.0
Soft tissue 50.3 < 0.001
No. of metastatic sites
1 30.9
2 25.3
>2 13.8 < 0.001
Disease-free interval
< 24 months 18.2
> 24 months 29.2 < 0.005
Performance status
0-1 28.1
2-3 14.5 < 0.001
CA 15-3
<30Uml-' 31.3
> 30 U ml-' 24.7 < 0.004
Hormone receptor status
ER+ 28.7
ER- 17.8 < 0.02
apdetermined using the log-rank test
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Figure 1 Overall survival curves of patients according to the disease extent
score. Although there are only nine patients with a score more than 15, an
advantage in overall survival is evident from patients with a low score
through to patients with higher scores. This difference was validated by the
log-rank test (P < 0.006)
patients (40%) had recurrence within 2 years aftermastectomy, and
87 (28%) had initial recurrence in bone, 116 (37%) in lung, 77
(25%) in liver and 32 (10%) in soft tissue. Thirty-three patients
(11%) presented with neoplastic pleural effusion, seven (2%) with
lymphangitis and three (1%) with abdominal dropsy. Eighty-one
patients (26%) had simultaneous recurrence in two metastatic sites,
28 (9%) in three or more. Disease extension according to the
Swenerton score was evaluated in 232 patients (74%). Tumourload
was not assessable in 41 patients (13%) because ofthe presence of
pleural effusion, lymphangitis or ascites and in the remaining 39
(13%) because ofinsufficient documentation. The median score for
disease extension was 5 (range 2-32). The last follow-up examina-
tion was September 1995, when 187 of the 312 patients included
(60%) had died. The median time of follow-up from first recur-
rence ofsurviving patients was 22.2 months (range 5-107+).
CA 15-3 levels according to site of metastasis and
disease extension
One hundred and ninety patients out of 312 (61%) had serum CA
15-3 levels above the reference range. CA 15-3 level was more
frequently elevated in patients with liver metastases (52 out of 72,
72%) as well as in those presenting with pleural effusion (26 out of
34, 76%) than in patient subgroups with lung (51 out of 81, 63%),
bone (46 out of 87, 53%) or skin/lymph node (9 out of 32, 28%)
involvement. A total of 117 patients out of 203 (58%) with only
one metastatic site had supranormal levels of CA 15-3, whereas
elevated marker values were recorded in 53 outof81 (65%) and 20
out of 28 (71%) of those with two or more disease sites respec-
tively. This increasing trend in CA 15-3 positivity did not attain
statistical significance by the Chi-square test (P =0.1). Conversely,
a significant stepwise increase in either CA 15-3 median levels
(only considering patients recruited and followed by our institu-
tion) or CA 15-3 positivity (including all patients enrolled) with the
increase oftumour load has been clearly shown (Table 2).
Logistic regression analysis showed that the presence ofpleural
effusion and the disease extent in liver, lung and bone are indepen-
dent factors in predicting elevated CA 15-3 levels. Conversely,
age, menopause, ER status and stage of primary tumour did not
enter the model (P < 0.001).
Overall survival evaluation - univariate analyses
The results of the survival analysis of patients grouped according
to the different potential prognostic factors one at a time are listed
in Table 3. Survival in patients with visceral metastases was found
to be poorer than in those with soft tissue or bone involvement.
Liver and skin/lymph node metastases represented the most
powerful prognostic factor for short and long survival, respec-
tively, while survival of patients with lung involvement was
similar to those with bone metastases. A progressive worsening of
survival was found from patients with one site of disease to
patients with two or more. Patients with pleural effusion as the
single site ofdisease showed a longer survival than those with lung
or bone involvement (data not shown). Other variables such as
poor performance status (PS), ER-negative tumour, short DFI
were also found to be negatively correlated to overall survival.
Elevated levels of CA 15-3 were significantly associated to poor
life expectancy in overall patients. Patient stratification according
to the disease extent identified at least three subgroups with sepa-
rate survival curves (Figure 1). An inverse correlation between
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overall survival and both CA 15-3 levels andpositivity and disease
extent is shown in Table 2.
Multivariate analysis for overall survival according to
the Cox's model
Variables that demonstrated a prognostic significance in univariate
analysis were further tested in a multiple regression analysis
according to Cox's model. PS, ER status, the presence of visceral
metastases, DFI and the disease extent confirmed their prognostic
role (beta values: 0.39, -0.50, 0.43, -0.04, 0.41; P<0.001).
Conversely, the number of metastatic sites and CA 15-3 serum
levels failed to demonstrate an independent role in predicting
survival. Neither age nor menopausal status at relapse entered
the model.
DISCUSSION
This study confirmed the good sensitivity ofCA 15-3 in advanced
breast cancer patients. Serum marker values significantly corre-
lated with the disease extent, and this strict relationship accounted
for the negative prognosis ofpatients with elevated levels.
The CA 15-3 sensitivity in our series was close to that reported
elsewhere (Safi et al, 1989; de Wit et al, 1992; Geraghty et al,
1992; Bombardieri et al, 1993; Hayes, 1993; Soletormos et al,
1993). We also confirmed the finding (Clark et al, 1987) that some
initial prognostic characteristics ofthe primary tumour, such as ER
status, remain to be significant for the development of subsequent
metastases. As expected, other prognostic factors, such as visceral
involvement, DFI, PS, and the number of disease sites have been
confirmed to significantly influence overall survival. On the
contrary, with respect to the aforementioned study (Clark et al,
1987), we were unable to demonstrate the negative impact of
lymph node involvement at diagnosis, probably because 35% of
data were not available.
As repeatedly observed, (Clark et al, 1987; Zinser et al, 1987;
Koenders et al, 1992; Gregory et al, 1993), cases with visceral
metastases and, particularly, liver involvement have been found to
have the worst prognosis. However, the multivariate survival
analysis clearly showed that the tumour load may also negatively
influence the life expectancy, independently from the dominant
site ofdisease.
The overall disease extent was assessed, in the present study,
using the method firstly described by Swenerton et al (1979) and
subsequently updated by Colomer et al (1989), who introduced
information determined from the CT scan. Using the same criteria,
we observed at least three patient subsets with divergent life
expectancies, confirming the availability of this method for the
overall tumour load determination.
The prognostic significance of CA 15-3 (Berruti et al, 1994)
may be because of its relationship with disease extent, or, alterna-
tively, the mucinous marker may reflect the state ofcell differenti-
ation and aggressiveness of the tumour (Saccani Jotti and
Bombardieri, 1990). The increase of either marker levels or the
frequency of supranormal values with the increase of tumour load
suggest that CA 15-3 values reflect the number of breast cancer
cells secreting the marker and its prognostic role is because of the
strict relationship with disease extent. This hypothesis is supported
by the finding that the prognostic influence of the marker is not
confirmed in the multivariate Cox model in which disease extent
and CA 15-3 were concomitantly tested.
The assessment of tumour load is time-consuming and often
difficult in practice. In this study, in fact, disease extent was not
evaluable in about 25% ofthe patients: 39 (12%) because ofinsuf-
ficient information and 41 (13%) because of non-measurable
disease (pleural effusion, lymphangitis or ascites). The relation-
ship between marker levels and disease extent supports the use of
CA 15-3 in this respect, allowing a strict monitoring of tumour
variation as a consequence oftreatment administration (Tondini et
al, 1988; Safi et al, 1989; Robertson et al, 1991). It should be
noted, however, that the circulating marker values in patients with
the same disease extent score were not homogeneous. We do not
think that clearance mechanisms accounted for this discrepancy as
patients with liver or renal impairment were not included. The
recent finding ofa spread presence ofantibody against mucines in
seraofpatients with breast cancermay offer apossible explanation
for the cases with high disease extent and low CA 15-3 levels
(Gourevitch et al, 1995).
The usefulness of serial CA 15-3 evaluation in the follow-up of
disease-free patients after mastectomy is debatable, mainly
because it was found to be unable to detect the early stages of
recurrence ofdisease. However, the relationship between CA 15-3
positivity at first relapse of disease and overall survival suggests
that the marker could selectively detect patients with poor prog-
nosis who may benefit from an early aggressive treatment.
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